【24h】

Vaccination of plasmid DNA encoding ORF81 gene of CJ strains of KHV

机译:KHV CJ菌株ORF81基因编码质粒DNA的疫苗接种

获取原文
获取原文并翻译 | 示例
           

摘要

In order to construct the recombinant plasmid of pIRES-ORF81, the nucleic acid isolated from Koi herpes virus-CJ (KHV-CJ) strains was used as a template to insert the ORF81 gene fragments amplified by PCR into the pIRES-neo, a kind of eukaryotic expression vector. Using Western blotting analysis, it was verified that ORF81 gene protein can be expressed correctly by pIRES-ORF81, after MFC cells were transfected. The recombinant plasmid pIRES-ORF81 was set into three immunization dose gradients: 1, 10, and 50 mu g/carp. Empty plasmid group, PBS group, and blank control group were set simultaneously. Giving intramuscular injections to healthy carps with an average body mass of 246 +/- 20 g, indirect ELISA was used to regularly determine antibody levels after three times immunization injection. Neutralizing antibodies were detected by neutralization assay. The results of inoculation tests showed that the pIRES-ORF81 recombinant plasmid can induce the production of carp-specific antibodies. The differences of immune effect between the three different doses of immune gradients were not significant (P > 0.05), but they can induce the production of neutralizing antibodies. After 25 d of inoculation, carp mortality of pIRES-neo empty vector treatment groups was 85%, while the carp mortality of eukaryotic expression recombinant plasmid pIRES-ORF81 injected with three different doses of immune gradients was 20, 17.5, and 12.5%, respectively. Differences in comparison to the control group were highly significant (P < 0.01). However, histopathological section of immunohistochemistry organization revealed no significant changes. It demonstrated that the DNA vaccine pIRES-ORF81 constructed in the experiment displayed a good protective effect against KHV, which had the potential to industrial applications
机译:为了构建pIRES-ORF81的重组质粒,使用从锦鲤疱疹病毒-CJ(KHV-CJ)菌株中分离的核酸作为模板,将通过PCR扩增的ORF81基因片段插入到pIRES-neo中。真核表达载体。使用蛋白质印迹分析,证实在转染MFC细胞后,pIRES-ORF81可以正确表达ORF81基因蛋白。将重组质粒pIRES-ORF81设置为三种免疫剂量梯度:1、10和50μg /鲤。同时设置空质粒组,PBS组和空白对照组。将肌肉注射至平均体重为246 +/- 20 g的健康鲤鱼,在进行三次免疫注射后,使用间接ELISA定期确定抗体水平。通过中和测定法检测中和抗体。接种试验结果表明,pIRES-ORF81重组质粒可诱导鲤鱼特异性抗体的产生。三种不同剂量的免疫梯度之间的免疫效果差异不显着(P> 0.05),但它们可以诱导中和抗体的产生。接种25天后,pIRES-neo空载体治疗组的鲤鱼死亡率为85%,而注射了三种不同剂量的免疫梯度的真核表达重组质粒pIRES-ORF81的鲤鱼死亡率分别为20%,17.5%和12.5%。 。与对照组相比差异非常显着(P <0.01)。但是,免疫组织化学组织的病理学切片显示无明显变化。结果表明,实验构建的DNA疫苗pIRES-ORF81具有良好的抗KHV保护作用,具有工业应用潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号